Case & reviewLichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists
Section snippets
Case 1
A 55-year-old male construction worker began infliximab for treatment of severe psoriatic arthritis and psoriasis affecting 5% of his body surface area. Treatment with infliximab reduced joint pain and swelling, leading to significant functional improvement. His skin improved except for trace residual plaques on the elbows and knees and a persistent lesion in the gluteal fold. His medical history was otherwise notable for hypertension, hypercholesterolemia, erectile dysfunction, and chronic
Discussion
We describe two patients who developed LP-like eruptions while on a TNF-α inhibitor for the treatment of psoriatic disease. Eleven similar cases have been previously reported in 10 patients,10, 11, 12, 13, 14, 15, 16, 17 including one patient who developed lichenoid reactions to both adalimumab and lenercept. Key features of these 13 eruptions in 12 patients are summarized in Table I. Lichenoid interface dermatitis was confirmed by histology in all cases.
The 12 patients were clinically diverse:
Conclusion
In summary, a growing body of evidence suggests that TNF-α inhibitors can trigger a wide variety of inflammatory disease states, including LP-like cutaneous and mucosal eruptions. Lichenoid reactions can occur within weeks of starting therapy, or may be delayed many months. Fortunately, these eruptions have a good prognosis. Some patients recover completely. Those who do not clear have shown at least partial improvement. Whether lichenoid eruptions are an indication to stop TNF-α inhibitor
References (34)
- et al.
Drug-induced lupus due to anti-tumor necrosis factor alpha agents
Semin Arthritis Rheum
(2008) - et al.
Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France
Joint Bone Spine
(2006) - et al.
Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases
Ann Dermatol Venereol
(2007) - et al.
Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus
J Invest Dermatol
(2004) - et al.
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients
Am J Clin Dermatol
(2008) - et al.
Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions
Arch Dermatol
(2007) - et al.
Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists
Br J Dermatol
(2007) - et al.
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases
Medicine (Baltimore)
(2007) - et al.
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors
Arch Dermatol
(2006) - et al.
Granuloma annulare induced by anti-tumor necrosis factor therapy
Ann Rheum Dis
(2008)
Acneiform eruption following anti-TNF-a treatment: a report of 3 cases
J Drugs Dermatol
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy
Dermatology
Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern
Arch Dermatol
Etanercept-induced lichenoid reaction pattern in psoriasis
J Dermatolog Treat
Clinical challenges and images in GI: oral lichenoid reaction in a patient with Crohn's disease receiving infliximab
Gastroenterology
Lichenoid reaction induced by adalimumab
J Eur Acad Dermatol Venereol
Lichen planus associated with etanercept
Br J Dermatol
Cited by (0)
Supported by a generous grant from Ms Joan Fabry. Tufts Medical Center has received educational/research grants from Centocor, Amgen, Wyeth, Immune Control, Celgene, Incyte, and Abbott.
Disclosure: Almost all of Dr Gottlieb's income is paid to her employer. Dr Gottlieb has speakers' bureau memberships with Amgen Inc and Wyeth Pharmaceuticals. Dr Gottlieb has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott Laboratories, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, DermiPsor, Can-Fite, Incyte, and Corgentech. Ms Fabry is a patient of Dr Gottlieb's and gave an unrestricted grant to support psoriasis research. Dr Massarotti receives consulting/honoraria from Bristol Myers Squibb, UCB, Genentech, Abbott, and PAI. Dr Bush has received research funding from Centocor. Mr Asarch, and Drs Lee, Masterpol, Scheinman, and Stadecker have no conflicts of interest to declare.
Case 1 was presented at a meeting of the New England Dermatological Society at Tufts Medical Center, Boston, MA, on December 1, 2007.